Scarica l'app Stockscreener
9.24
2.67%
0.24
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VIR Giù?
Forum
Previsione
Precedente Chiudi:
$9.00
Aprire:
$9
Volume 24 ore:
1.02M
Relative Volume:
0.56
Capitalizzazione di mercato:
$1.56B
Reddito:
$68.56M
Utile/perdita netta:
$-437.99M
Rapporto P/E:
-2.9204
EPS:
-3.1639
Flusso di cassa netto:
$-396.61M
1 W Prestazione:
+4.76%
1M Prestazione:
-2.63%
6M Prestazione:
+23.69%
1 anno Prestazione:
+108.11%
Intervallo 1D:
$8.80
$9.27
Intervallo di 1 settimana:
$8.771
$9.27
Portata 52W:
$4.25
$11.66
Vir Biotechnology Inc Stock (VIR) Company Profile
Nome
Vir Biotechnology Inc
Settore
Industria
Telefono
415-906-4324
Indirizzo
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
9.24 | 1.52B | 68.56M | -437.99M | -396.61M | -3.1639 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-09-03 | Iniziato | Evercore ISI | Outperform |
| 2025-08-27 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-01-29 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-09-08 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-03-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-02-21 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-01-27 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | Iniziato | SVB Leerink | Outperform |
| 2022-09-09 | Iniziato | Morgan Stanley | Underweight |
| 2022-03-03 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-09-22 | Downgrade | Goldman | Buy → Neutral |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-01-27 | Downgrade | JP Morgan | Neutral → Underweight |
| 2021-01-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-05 | Iniziato | BofA Securities | Buy |
| 2020-09-14 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-09-11 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-08-20 | Iniziato | Needham | Buy |
| 2020-03-19 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-03-13 | Downgrade | Goldman | Buy → Neutral |
| 2020-02-27 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-11-14 | Iniziato | Robert W. Baird | Neutral |
| 2019-11-05 | Iniziato | Barclays | Overweight |
| 2019-11-05 | Iniziato | Cowen | Outperform |
| 2019-11-05 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Vir Biotechnology Inc Borsa (VIR) Ultime notizie
VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership - Stocktwits
Vir Biotechnology, Inc. (VIR) Stock Forecasts - Yahoo Finance
Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript - The Globe and Mail
Vir Biotechnology (VIR) director restructures 16,000-share holding with Alta Partners fund - Stock Titan
Equities Analysts Offer Predictions for VIR Q3 Earnings - marketbeat.com
Vir Biotechnology: Astellas Deal Pushes Cash Above $1 Billion And Extends Runway Into Second Half Of 2028 - Pulse 2.0
Vir Biotechnology (NASDAQ:VIR): What’s Driving Fresh Attention? - Kalkine Media
Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Why Did Vir Biotechnology Stock Surge 60% After-Hours Today? - Stocktwits
H.C. Wainwright reiterates Vir Biotechnology stock rating on trial progress By Investing.com - Investing.com Canada
Vir Biotechnology Inc (VIR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Vir Biotechnology (VIR) Receives a Buy from Bank of America Securities - The Globe and Mail
What Vir Biotechnology (VIR)'s Profit Swing But Earnings Miss Means For Shareholders - simplywall.st
Vir Biotechnology (NASDAQ:VIR) Stock Rating Upgraded by Wall Street Zen - MarketBeat
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $15 to $30 - Moomoo
Vir Biotechnology (VIR): State Street discloses 9.96M-share, 5.9% ownership position - Stock Titan
Understanding Momentum Shifts in (VIR) - Stock Traders Daily
Vir Biotechnology, Inc. Stock 12‑Month Price Target Cut to $21, Implies 140% Upside - TradingView
Vir Biotechnology Inc (VIR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Vir Biotechnology, Inc. (VIR) Stock Analysis: Unpacking a 140% Potential Upside for Investors - DirectorsTalk Interviews
Vir Biotechnology, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
VIR Looks 63.2% Undervalued on GF Value™ - GuruFocus
Vir Biotechnology Q2 Earnings Call Highlights - MarketBeat
VIR SWOT Analysis: Financial Resilience Amidst Clinical Challenges Revealed in 10-Q Filing - GuruFocus
Vir Biotechnology Inc (VIR) (Q2 2026) Earnings Call Highlights: - GuruFocus
Vir Biotechnology Inc (VIR) (Q2 2026) Earnings Call Highlights: 88% HDV Cure Rate and a $1B ... - Yahoo Finance
VIR Looks 62.9% Undervalued on GF Value™ Despite Unprofitable St - GuruFocus
Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates - Yahoo Finance
Earnings call transcript: Vir Biotechnology jumps on q2 2026 cash and data gains - Investing.com
Vir Biotechnology, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Is Vir Biotechnology Inc (VIR) Undervalued After Q2 Earnings? EP - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Posts Quarterly Earnings Results, Beats Estimates By $0.14 EPS - MarketBeat
Vir Biotechnology Q2 2026 slides: hepatitis delta, oncology gains - Investing.com
Vir Biotechnology (VIR) Releases Q2 2026 Earnings: Revenue and EPS Beat Estimates - Quiver Quantitative
Vir Biotechnology Inc. (VIR) Tops Q2 EPS by 14c - StreetInsider
Vir Biotechnology 2Q 2026: Revenue $238.95M, Net income $80.08M, EPS $0.47— 10-Q Summary - TradingView
Vir Biotechnology (NASDAQ: VIR) swings to profit on $239.3M Astellas deal - Stock Titan
Earnings Flash (VIR) Vir Biotechnology, Inc. Reports Q2 Revenue $238.9M - marketscreener.com
Vir Biotechnology Q2 revenue up, beats estimates on Astellas payment - TradingView
Vir Biotechnology posts $238.9M Q2 revenue, $80.1M net income; $1.01B cash runway into H2 2028 - TradingView
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results - marketscreener.com
Investors brace for Vir Biotech earnings amid turnaround bid By Investing.com - Investing.com Nigeria
Renaissance Technologies LLC Increases Stake in Vir Biotechnology, Inc. $VIR - MarketBeat
Earnings To Watch: Vir Biotechnology Inc (VIR) Q2 2026 -- GF Value Sees 175% Upside - Yahoo Finance
Public Employees Retirement System of Ohio Acquires Shares of 112,700 Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology Inc expected to post earnings of 33 cents a shareEarnings Preview - TradingView
950,000 Shares in Vir Biotechnology, Inc. $VIR Bought by Avidity Partners Management LP - MarketBeat
Vir Biotechnology (VIR) Could Be 60% Undervalued On CFO Transition - Yahoo Finance
Vir Biotechnology (VIR) Expected to Post Earnings on Wednesday - MarketBeat
Eversept Partners LP Takes $2.24 Million Position in Vir Biotechnology, Inc. $VIR - MarketBeat
Empyrean Capital Partners LP Invests $4.73 Million in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology Inc Azioni (VIR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):